Background. In December 2009, the Department of Health and Human Services guidelines for initiation of antiretroviral therapy (ART) changed to include patients with CD4 counts between 350 and 500 cells/µL. The aims of this study were to assess uptake of this recommendation in ART-naive youth with human immunodeficiency virus (HIV) and to describe the epidemiology of transmitted genotypic drug resistance mutations (DRMs) in this population.
The optimal time to initiate antiretroviral therapy (ART) in adolescents with human immunodeficiency virus (HIV) has not been studied in randomized trials; therefore, current HIV treatment recommendations for adolescents follow adult guidelines. Adolescents and young adults aged 13-24 years are one of the fastestgrowing demographic groups acquiring new infections, with 25 .7% of all new HIV diagnoses occurring in this age group [1] . Trends in viral resistance patterns, initial CD4 count, and plasma RNA in this younger HIVinfected population in the United States have not been studied in depth.
The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents made recommendations for earlier initiation of ART; in December 2009, the DHHS recommended ART initiation at a CD4 count of <500 cells/ µL [2] . Of note, the panel was divided, as 55% of panel members voted for a strong recommendation (A) and 45% for a moderate recommendation (B) [2] . In February 2013, the panel recommended treatment for all HIV-infected individuals regardless of CD4 count [3] . Timely initiation of ART initiation aims to prevent HIV-associated morbidity and mortality, to decrease HIV transmission, and in patients with higher CD4 counts, to prevent non-AIDS-defining diseases including malignancy and kidney, liver, neurologic, and cardiovascular diseases from uncontrolled viremia [3] .
Data from the Centers for Disease Control and Prevention show that adolescents generally present to care with higher CD4 counts than adults [4] . The potential benefits or risks of initiating ART earlier in this younger population are unknown and are complicated by developmental and psychosocial factors unique to this age group. Timely initiation of ART in adults has increased in the last decade [5] , but ART initiation is less well studied in adolescents.
Various reports have found that the rate of drug resistance mutations (DRMs) is 6%-17% among ART-naive HIV-infected adolescents and adults in the United States and 5% in developing countries [6] [7] [8] [9] [10] [11] . One study reported specifically on the rate of DRMs in HIV-infected youth in the United States; 18% (10/55) of recently HIV-infected adolescents and young adults had transmitted genotypic DRMs identified [12] . The objectives of this study were to describe the CD4 count, viral load, and prevalence of DRMs in ART-naive, recently diagnosed HIV-infected adolescents and young adults in New York City. We hypothesized that after the DHHS guideline change in 2009, >50% of ART-naive adolescents and young adults had a CD4 count in the range recommended to begin treatment (ie, <500 cells/µL). We further hypothesized that approximately 15% would have major DRMs prior to initiation of ART.
METHODS

Study Design, Study Sites, and Study Subjects
This was a multicenter, retrospective cohort study of HIVinfected, ART-naive youth at 4 HIV clinics in New York City. The study sites were (i) the Health and Education Alternatives for Teens (HEAT) Program at SUNY Downstate in Brooklyn; (ii) the Health Outreach to Teens (HOTT) Program and adult program at Callen-Lorde Community Health Center, in the Chelsea neighborhood of Manhattan; (iii) Project Services to Assist Youth (STAY) at Columbia University Medical Center in the Washington Heights neighborhood of Manhattan; and (iv) the Comprehensive HIV-Infectious Disease Clinic (IDC) at Columbia University Medical Center in Washington Heights. The 2 Columbia University sites were combined in the analysis. Subjects seen at >1 study site were included with the site where they first entered HIV care. Institutional review board approval with a waiver of informed consent was obtained at each study site.
Inclusion criteria: Subjects were eligible if they (i) were 13-25 years of age; (ii) contracted HIV via sexual contact or intravenous drug use; (iii) were diagnosed with HIV within 1 year of presentation to care at the study sites; and (iv) presented to care from January 2007 to June 2011.
Exclusion criteria: Subjects were excluded from the study for the following reasons: (i) ART use before presentation to care defined as prior treatment, preexposure prophylaxis, or postexposure prophylaxis; (ii) perinatal HIV infection; (iii) transfusionrelated HIV infection; (iv) conditions for which immediate initiation of ART is recommended regardless of CD4 count including hepatitis B coinfection, HIV nephropathy, pregnancy, or history of AIDS-defining illness [13] ; or (iv) received primary HIV care elsewhere and seen at a study site for an issue unrelated to initiation of HIV care (eg, anoscopy or treatment of another sexually transmitted infection).
Data Collection
Each study site provided a list of potential subjects within the specified age range who presented to care from January 2007 to June 2011. Medical records review was conducted by members of the study team not directly involved in care of potential subjects to determine eligibility and to extract relevant data.
Subjects' demographic information including age, race/ethnicity, sexual orientation, and transmission risk factors were extracted from clinic intake forms, physician notes, case manager notes, and Department of Health reporting forms. The date of HIV diagnosis was used as the HIV-care start date for eligible subjects if they were already in care at one of the study sites prior to their HIV diagnosis.
Laboratory Measurements
CD4 count and plasma RNA were recorded at entry into care, prior to initiation of ART, and until 6 months (±2 months if 6-month data were not available) after initiation of ART.
Detection limits of the commercial assays varied over the study period [14] . Undetectable plasma RNA was defined as less than the lower limit of detection of the assay used (Supplementary Table 1 ).
ART Initiation
Date of ART initiation and regimen were recorded until 31 December 2011. Changes in ART regimen within 6 months of initiation and reason for the change were recorded, when available. Clinical eligibility for initiation of ART was defined by the DHHS treatment guidelines in place from January 2007 through December 2009 (ie, CD4 <350 cells/µL) vs those in place from January 2010 through December 2011 (ie, CD4 <500 cells/µL) [2] .
Resistance Testing Prior to Starting ART
Genotypic drug resistance mutations were determined using the Monogram Biosciences GeneSeq HIV drug resistance assay (South San Francisco, California). Major DRMs were defined using the 2013 International Antiviral Society Update of the Drug Resistance Mutations in HIV-1, the 2009 World Health Organization reference list of transmitted drug resistance mutations, and the Stanford guide [15] [16] [17] . For amino acid positions at a site of major resistance, but with an atypical substitution, the Stanford guide was used to determine those likely associated with drug resistance [16, 17] . Resistance data were collected on all subjects with available testing, including those not started on ART. Only data on resistance testing done prior to ART initiation were collected.
Statistical Analysis
The χ 2 test, Fisher exact test, or t test was used to compare the characteristics of study subjects, their CD4 counts, plasma RNA, and the presence of a major DRM. When analyzing immunologic and virologic characteristics at the time of ART initiation, subjects were included in the period in which they initiated ART, regardless of when they entered care. When analyzing major drug mutations, subjects were included in the year in which the resistance testing was performed. Simple logistic regression was used to determine potential factors including sex, age of entry into care (13-19 years vs 20-25 years), ethnicity, race, transmission risk factor, and study site associated with major mutations. Significance was determined at the .05 level. Response to ART measured by plasma RNA after 6 months of ART was also studied. All analysis was performed using SAS software, version 9.3.
RESULTS
Characteristics of the Subjects
Of 685 potential subjects identified, 331 (48%) fulfilled inclusion criteria, including 5 who started care at one study site and transitioned care to another study site (Figure 1 ). There was a significant difference in the number of eligible subjects for inclusion identified at each study site (P = .005). The HEAT Program identified 112 potential subjects, of whom 49 (44%) were included; Callen-Lorde identified 377 potential subjects, of whom 203 (54%) were included; and the Columbia University sites Project STAY and IDC identified 196 potential subjects, of whom 79 (40%) were included. The characteristics of the included study subjects are shown in Table 1 .
CD4 Count and Plasma RNA Level at Presentation to Care
The 33% (75/232) of subjects had a CD4 count <350 cells/µL, and thus fulfilled criteria for ART initiation in place during this time period. In 2010-2011, 57% (56/99) of subjects had a CD4 count <500 cells/µL and fulfilled criteria for ART initiation in place during this later time period. At presentation to care, 1.5% (5/331) of subjects had undetectable plasma RNA and an additional 2.1% (7/331) achieved undetectable plasma RNA even prior to starting ART. The mean plasma RNA at presentation to care was 126 801 copies/mL. The mean plasma RNA in 2007-2009 vs 2010-2011 was similar (P = .8; Table 1 ).
ART Initiation
A total of 191 (58%) subjects started ART (Table 2 ). There was a difference in CD4 count at ART initiation during 2007-2009 vs 2010-2011 (261 cells/µL vs 363 cells/µL, respectively; P < .0001), but the plasma RNA at ART initiation was similar (P = .4). In 2010-2011, subjects were more likely to be started on ART when the CD4 count was 350-500 cells/µL or >500 cells/µL than those subjects started in 2007-2009 in the same CD4 categories (odds ratio, 5.2 [95% confidence interval, 1.1-25.1]). The overall mean time between when subjects became eligible for ART, by relevant CD4 thresholds, to ART initiation was 4.8 months (range, 0-48 months).
Six-Month Plasma RNA Level After ART Initiation
Six months after ART initiation, 116 (71%) subjects had undetectable plasma RNA. The proportion of subjects with undetectable plasma RNA 6 months after ART initiation was similar in 2007-2009 vs 2010-2011 (P = .97). The mean time to achieve undetectable plasma RNA after initiation of ART was 147 days (range, 11-665). In subjects started on ART with a CD4 count <350 cells/µL (n = 147), 350-500 cells/µL (n = 37), and CD4 >500 cells/µL (n = 13), the mean time to undetectable plasma RNA was 158 days (range, 11-563), 131 days (range, 22-444), and 77 days (range, 29-155), respectively. There was no difference in time to undetectable plasma RNA between the groups (P = .12).
ART Regimens Initiated
Emtricitabine/tenofovir/efavirenz was the most common ART regimen initiated during both periods (Table 3) . Three (2%) participants changed regimens within 6 months of initiating ART, all of whom were initially started on emtricitabine/tenofovir/efavirenz. One regimen was changed to raltegravir and lamivudine/zidovudine after 1 month due to dizziness, the second was changed to atazanavir, ritonavir, and emtricitabine/tenofovir after 3 months due to rash, and the third was changed to emtricitabine/rilpivirine/tenofovir after 2 months for an unknown reason. Among the 15 female subjects in the study, 7 were started on ART: 3 on protease inhibitor (PI)-based regimens, 3 on raltegravir-based regimens, and 1 on an efavirenzcontaining regimen.
Drug Resistance Mutations
Of 331 eligible subjects, 212 (64%) had resistance testing performed ( Figure 1 ). Characteristics of those with and without resistance testing available were comparable for age at entry to care, ethnicity, race, and transmission risk factors (data not shown). Resistance testing was less commonly performed for female subjects (P = .047) and varied by site (P = .0008). However, those started on ART were more likely to have resistance testing performed than those not started on ART (78% [149/191] vs 45% [63/140]; P < .0001; Figure 1 ). The mean time from presentation to care to resistance testing was 3.9 months (range, 0-43 months). When the presence of major drug mutations were analyzed by the year that resistance testing was performed, the (12) 6 (8) 17 (15) Atazanavir, ritonavir, emtricitabine/tenofovir 22 (11) 7 (9) 15 (13) Darunavir, ritonavir, emtricitabine/tenofovir 9 (5) 1 (1) 8 (7) Lopinavir/ritonavir, emtricitabine/tenofovir Figure 2 ). Fifty major DRMs were detected in 38 of 212 (18%) participants with resistance testing available (Table 4) . Nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations were the most common major DRMs (60%). Four subjects had 2-class resistance (2 NNRTI/nucleoside reverse transcriptase inhibitor [NRTI], 1 NNRTI/PI, 1 PI/NRTI), and none had 3-class resistance. Four of 5 subjects with rilpivirine DRMs had these resistance mutations prior to Food and Drug Administration approval of this agent in 2011.
Minor DRMs were detected in 62 (30%) subjects (data not shown). Characteristics of subjects with and without major mutations were similar with respect to sex (P = .93), age on entry into care (13-19 vs 20-25 years; P = .84), ethnicity (P = .63), race (P = .11), transmission risk factor (P = .72), and study site (P = .72).
DISCUSSION
In this large retrospective cohort study of recently diagnosed, ART-naive young adults and adolescents with HIV in NYC, we found a significant increase in the mean CD4 count at initiation of ART after the DHHS guidelines changed in December 2009. As hypothesized, >50% of subjects entering care from 20007-2009 fulfilled CD4 criteria to initiate ART as recommended by the 2009 guidelines. Figure 2 . Proportion of subjects with drug resistance mutations (DRM) by year of resistance testing. Note that 5 subjects were tested in 2012 and 2 had DRMs. These subjects are combined with subjects in 2011. Abbreviations: NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. a E138A is a polymorphism that may contribute to reduced etravirine and rilpivirine susceptibility in combination with other NNRTI-resistance mutations. E138K and A are nonpolymorphic accessory resistance mutations selected in vitro and in vivo by raltegravir and elvitegravir, usually in combination with Q148 mutations [18] . Alone, they do not reduce integrase inhibitor susceptibility, but in combination with Q148 mutations they reduce raltegravir and elvitegravir susceptibility >100-fold [19] . They were included because they can confer rilpivirine resistance [15] . b Mutations other than Y and F at position 215 (215 revertants) were included as major drug resistance mutations. Although 215 revertants do not reduce NRTI susceptibility, a single mutation can cause emergence of T215F or Y and renders some regimens less effective and increases risk of virologic failure [20, 21] .
The DHHS guidelines are based on data that show ART initiation reduces morbidity and mortality [22] [23] [24] [25] [26] [27] [28] [29] , prevents perinatal transmission [30] , and potentially reduces behaviorassociated transmission [31] [32] [33] [34] . Furthermore, data suggest that there is a decreased risk for selection of resistant virus if ART is initiated earlier [35] . The sequelae of HIV viremia, chronic inflammation, and immune activation can cause endorgan damage that may be prevented by earlier initiation of ART [26, [36] [37] [38] [39] . Subjects with CD4 counts 350-500 cells/µL and >500 cells/µL were more likely to be started on ART from 2010 to 2011 than from 2007 to 2009, which could reflect a trend toward earlier initiation due to increasing evidence supporting earlier ART initiation. This finding may have beneficial implications for acceptance and uptake of the 2013 DHHS guidelines.
In our cohort of 212 ART-naive adolescents and young adults with available resistance testing, 18% had major DRMs prior to initiation of ART. This rate is comparable to the findings of Viani and colleagues, who reported an 18% rate of major DRMs among HIV-infected ART-naive adolescents in the United States [12] . In contrast, Agwu and colleagues reported a 9.2% prevalence of DRMs in youths aged 18-24 years, but it is likely this rate underestimated the prevalence of DRMs as subjects with several major mutations were excluded [40] . In addition, we found that 2% of subjects had 2-class resistance, whereas Agwu et al found ≥2-class resistance in 7.7% of subjects. The difference could be related to the different geographic regions included; our study was confined to New York City, whereas Agwu et al's study included sites around the United States.
Our data suggest an increasing rate of resistance in ARTnaive individuals from 2007-2009 to [2010] [2011] (Figure 2 ). NNRTI DRMs were most prevalent (14%), consistent with other studies [12] . We did not identify any risk factors associated with major DRMs. The prevalence of minor DRMs was 30%, and these may become significant as new drugs are introduced.
Although we did not assess the rationale for ART regimens chosen, we found it interesting that 25 (13%) subjects were started on raltegravir-containing regimens (Table 3) . Among these, 12 subjects did not have a major DRM, 6 had K103N mutations (2 of which had 2-class resistance), 4 subjects did not have resistance testing done, and 1 subject (also with no major DRMs) was started on a raltegravir-containing regimen as part of a research protocol. Although resistance profiles may have guided the choice of ART regimen in those that had major DRMs, the December 2009 guidelines were the first to include raltegravir-containing regimens as a "preferred" regimen [2] , possibly influencing increased use during 2010-2011.
This study had some limitations. Our findings may not be generalizable to other HIV care sites. Each site used a different methodology to identify potential subjects. Subjects with AIDSdefining illnesses may have been underestimated due to incomplete documentation, but we speculate this is less likely as our subjects were recently diagnosed with HIV. ART adherence was not measured, which could have impacted virologic suppression. We did not assess the rationale for initiating or not initiating ART in those who were eligible or the rationale for the regimens chosen. Only 60% of participants had available resistance testing results, which may reflect missing data, particularly during the earlier years of the study, rather than failure to perform testing. However, more subjects started on ART had resistance testing performed, which suggests a treatment bias associated with obtaining the testing. In addition, potential patient factors that could be risk factors for a major DRM were not all evaluated. Furthermore, the level of plasma RNA could also confound detection of DRMs.
In conclusion, our findings demonstrate uptake in the 2009 ART initiation guidelines. The DRM data have implications for choosing initial regimens for ART-naive adolescents and young adults. Monitoring the epidemiology of HIV DRMs will inform future treatment guidelines, and our findings reinforce the recommendation to perform HIV resistance testing upon entry into care [3] .
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